Ascendis Pharma's YUVIWEL Receives FDA Orphan Drug Exclusivity
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy ASND?
Source: NASDAQ.COM
- Orphan Drug Designation: Ascendis Pharma's lead asset YUVIWEL has been granted orphan drug exclusivity by the FDA, valid until February 27, 2033, providing a crucial window for revenue generation and patient adoption in the market.
- Market Uniqueness: YUVIWEL is the first FDA-approved once-weekly treatment for children aged two and older with achondroplasia, presenting significant differentiation potential that is expected to attract a large patient base.
- Clinical Validation Requirements: Despite receiving approval, continued market authorization for YUVIWEL will depend on verification of clinical benefits in confirmatory trials, indicating that the company must conduct further clinical research to ensure long-term success.
- Stock Performance: Ascendis Pharma's stock has traded between $124.06 and $248.60 over the past year, closing at $226.69, down 1.12%, yet still reflecting market confidence in its product offerings.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ASND?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ASND
Wall Street analysts forecast ASND stock price to rise
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 220.480
Low
240.00
Averages
277.08
High
342.00
Current: 220.480
Low
240.00
Averages
277.08
High
342.00
About ASND
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ascendis Pharma Plans Direct Listing on Nasdaq
- Direct Listing Announcement: Ascendis Pharma has announced plans to directly list its ordinary shares on Nasdaq starting April 20, 2026, with all existing American Depositary Shares (ADSs) being exchanged for ordinary shares, aiming to broaden global investor participation and enhance the company's market position.
- Simplified Trading Structure: Each ADS will be exchanged for one ordinary share, which will trade under the existing ticker symbol 'ASND' on Nasdaq, and this simplified listing structure is expected to increase institutional ownership and trading liquidity for the shares.
- New Security Identifiers: The ordinary shares will have a new CUSIP number K08588103 and ISIN DK0060606333, replacing the existing ADS identifiers, which will help improve investor recognition and acceptance of the ordinary shares.
- Risk Considerations: While the company is optimistic about the direct listing, various risks remain, including potential delays in listing and liquidity issues, which could affect trading dynamics and investor expectations regarding the ordinary shares.
See More
Ascendis Pharma's YUVIWEL Receives FDA Orphan Drug Exclusivity
- Orphan Drug Designation: Ascendis Pharma's lead asset YUVIWEL has been granted orphan drug exclusivity by the FDA, valid until February 27, 2033, providing a crucial window for revenue generation and patient adoption in the market.
- Market Uniqueness: YUVIWEL is the first FDA-approved once-weekly treatment for children aged two and older with achondroplasia, presenting significant differentiation potential that is expected to attract a large patient base.
- Clinical Validation Requirements: Despite receiving approval, continued market authorization for YUVIWEL will depend on verification of clinical benefits in confirmatory trials, indicating that the company must conduct further clinical research to ensure long-term success.
- Stock Performance: Ascendis Pharma's stock has traded between $124.06 and $248.60 over the past year, closing at $226.69, down 1.12%, yet still reflecting market confidence in its product offerings.
See More
RBC Capital Markets Lists 13 Biotechs Likely to Attract Takeover Interest
- Acquisition Potential Analysis: RBC Capital Markets analyst Leonid Timashev highlighted that approximately 85 reports on biotech acquisitions have surfaced since 2021, indicating sustained acquisition interest in the sector, particularly for companies like Revolution Medicines (RVMD), Ascendis Pharma (ASND), and Arrowhead Pharma (ARWR).
- Media Impact Variability: Timashev analyzed M&A commentary from four major publications and found that Betaville's hit rate was only 20%-30%, while others achieved hit rates of 60%-70%, demonstrating significant differences in the accuracy and influence of various media on acquisition news.
- Investment Return Potential: Reports from Bloomberg and the Financial Times showed a median return of 27% over 30 days, with the FT's return soaring to 70% over 90 days, underscoring the profound impact of M&A activities on investor returns in the biotech sector.
- Potential Acquirers List: Timashev also identified Merck (MRK), AbbVie (ABBV), and Bristol Myers Squibb (BMY) as the most likely potential buyers, indicating a rising interest from large pharmaceutical companies in acquiring biotech firms.
See More
Ascendis Pharma Reports Positive Phase 2 Trial Results for TransCon hGH
- Clinical Trial Results: Ascendis Pharma's Phase 2 trial, New InsiGHTS, shows that TransCon hGH achieves an annualized height velocity (AHV) of 9.05 cm/year over 52 weeks, comparable to daily somatropin, indicating its efficacy in treating children with Turner syndrome.
- Safety Assessment: The safety and tolerability profile of TransCon hGH is similar to that of daily somatropin, with no severe adverse events leading to discontinuation observed during follow-up of up to 143 weeks, demonstrating its long-term safety.
- Dose Comparison: In the trial, the mean dose for TransCon hGH was 0.22 mg/kg/week, while the daily somatropin cohort received a mean dose of 0.29 mg/kg/week, suggesting a potential dosing advantage for TransCon hGH.
- Future Research Plans: Ascendis Pharma is conducting the Phase 3 HighLiGHts trial to support label expansion for TransCon hGH across multiple indications, including Turner syndrome, Idiopathic Short Stature, SHOX Deficiency, and Small for Gestational Age, highlighting the company's focus on the drug's future market potential.
See More
FDA Grants Approvals for Multiple New Therapies
- Hernexeos Approval: On February 26, 2026, the FDA granted accelerated approval to Boehringer Ingelheim's Hernexeos as a first-line treatment for adult patients with HER2-mutant advanced non-small cell lung cancer, representing a significant milestone that could improve patient prognosis and reduce the risk of brain metastases for the 2-4% of NSCLC cases affected.
- Yuviwel Launch: Ascendis Pharma secured FDA approval on February 27, 2026, for Yuviwel, the first and only therapy providing continuous systemic exposure to C-type natriuretic peptide (CNP) for children aged 2 and older with achondroplasia, which is expected to enhance treatment adherence compared to daily alternatives.
- Palynziq Indication Expansion: BioMarin received FDA approval on February 27, 2026, to expand Palynziq's indication to include pediatric patients aged 12 and older with phenylketonuria, which is anticipated to further drive sales growth, having generated $433 million in revenue in 2025.
- Sogroya New Indications: Novo Nordisk obtained FDA approval on February 27, 2026, for Sogroya's expanded indications for various growth disorders, offering a once-weekly growth hormone alternative that is expected to improve treatment adherence and alleviate the burden of daily injections for families.
See More
Ascendis Pharma Plans 2026 U.S. Launch of YUVIWEL Following FDA Approval
- FDA Approval Milestone: Ascendis Pharma's YUVIWEL has received FDA approval as the first once-weekly treatment for children with achondroplasia, marking the company's third FDA-approved drug and significantly enhancing its competitive position in the rare disease market.
- Clinical Data Highlights: In the pivotal ApproaCH trial, children treated with navepegritide achieved an annualized growth velocity (AGV) of 5.9 cm/year compared to 4.4 cm/year for placebo, demonstrating a significant treatment difference of 1.5 cm/year, indicating the drug's clinical efficacy.
- Commercialization Strategy: Ascendis plans to support the commercial availability of YUVIWEL in early Q2 2026, expecting a premium pricing strategy, and aims to maximize market penetration through the Ascendis Signature Access Program, which includes reimbursement support and patient assistance.
- Market Opportunity and Future Milestones: Ascendis estimates approximately 2,600 pediatric patients with achondroplasia in the U.S., with plans to complete enrollment in a study for children aged 0-2 by 2026 and aims for European approval by the end of the year, further expanding market potential.
See More
Ascendis Pharma Plans Direct Listing on Nasdaq
- Direct Listing Announcement: Ascendis Pharma has announced plans to directly list its ordinary shares on Nasdaq starting April 20, 2026, with all existing American Depositary Shares (ADSs) being exchanged for ordinary shares, aiming to broaden global investor participation and enhance the company's market position.
- Simplified Trading Structure: Each ADS will be exchanged for one ordinary share, which will trade under the existing ticker symbol 'ASND' on Nasdaq, and this simplified listing structure is expected to increase institutional ownership and trading liquidity for the shares.
- New Security Identifiers: The ordinary shares will have a new CUSIP number K08588103 and ISIN DK0060606333, replacing the existing ADS identifiers, which will help improve investor recognition and acceptance of the ordinary shares.
- Risk Considerations: While the company is optimistic about the direct listing, various risks remain, including potential delays in listing and liquidity issues, which could affect trading dynamics and investor expectations regarding the ordinary shares.
See More
Ascendis Pharma's YUVIWEL Receives FDA Orphan Drug Exclusivity
- Orphan Drug Designation: Ascendis Pharma's lead asset YUVIWEL has been granted orphan drug exclusivity by the FDA, valid until February 27, 2033, providing a crucial window for revenue generation and patient adoption in the market.
- Market Uniqueness: YUVIWEL is the first FDA-approved once-weekly treatment for children aged two and older with achondroplasia, presenting significant differentiation potential that is expected to attract a large patient base.
- Clinical Validation Requirements: Despite receiving approval, continued market authorization for YUVIWEL will depend on verification of clinical benefits in confirmatory trials, indicating that the company must conduct further clinical research to ensure long-term success.
- Stock Performance: Ascendis Pharma's stock has traded between $124.06 and $248.60 over the past year, closing at $226.69, down 1.12%, yet still reflecting market confidence in its product offerings.
See More
RBC Capital Markets Lists 13 Biotechs Likely to Attract Takeover Interest
- Acquisition Potential Analysis: RBC Capital Markets analyst Leonid Timashev highlighted that approximately 85 reports on biotech acquisitions have surfaced since 2021, indicating sustained acquisition interest in the sector, particularly for companies like Revolution Medicines (RVMD), Ascendis Pharma (ASND), and Arrowhead Pharma (ARWR).
- Media Impact Variability: Timashev analyzed M&A commentary from four major publications and found that Betaville's hit rate was only 20%-30%, while others achieved hit rates of 60%-70%, demonstrating significant differences in the accuracy and influence of various media on acquisition news.
- Investment Return Potential: Reports from Bloomberg and the Financial Times showed a median return of 27% over 30 days, with the FT's return soaring to 70% over 90 days, underscoring the profound impact of M&A activities on investor returns in the biotech sector.
- Potential Acquirers List: Timashev also identified Merck (MRK), AbbVie (ABBV), and Bristol Myers Squibb (BMY) as the most likely potential buyers, indicating a rising interest from large pharmaceutical companies in acquiring biotech firms.
See More
Ascendis Pharma Reports Positive Phase 2 Trial Results for TransCon hGH
- Clinical Trial Results: Ascendis Pharma's Phase 2 trial, New InsiGHTS, shows that TransCon hGH achieves an annualized height velocity (AHV) of 9.05 cm/year over 52 weeks, comparable to daily somatropin, indicating its efficacy in treating children with Turner syndrome.
- Safety Assessment: The safety and tolerability profile of TransCon hGH is similar to that of daily somatropin, with no severe adverse events leading to discontinuation observed during follow-up of up to 143 weeks, demonstrating its long-term safety.
- Dose Comparison: In the trial, the mean dose for TransCon hGH was 0.22 mg/kg/week, while the daily somatropin cohort received a mean dose of 0.29 mg/kg/week, suggesting a potential dosing advantage for TransCon hGH.
- Future Research Plans: Ascendis Pharma is conducting the Phase 3 HighLiGHts trial to support label expansion for TransCon hGH across multiple indications, including Turner syndrome, Idiopathic Short Stature, SHOX Deficiency, and Small for Gestational Age, highlighting the company's focus on the drug's future market potential.
See More
FDA Grants Approvals for Multiple New Therapies
- Hernexeos Approval: On February 26, 2026, the FDA granted accelerated approval to Boehringer Ingelheim's Hernexeos as a first-line treatment for adult patients with HER2-mutant advanced non-small cell lung cancer, representing a significant milestone that could improve patient prognosis and reduce the risk of brain metastases for the 2-4% of NSCLC cases affected.
- Yuviwel Launch: Ascendis Pharma secured FDA approval on February 27, 2026, for Yuviwel, the first and only therapy providing continuous systemic exposure to C-type natriuretic peptide (CNP) for children aged 2 and older with achondroplasia, which is expected to enhance treatment adherence compared to daily alternatives.
- Palynziq Indication Expansion: BioMarin received FDA approval on February 27, 2026, to expand Palynziq's indication to include pediatric patients aged 12 and older with phenylketonuria, which is anticipated to further drive sales growth, having generated $433 million in revenue in 2025.
- Sogroya New Indications: Novo Nordisk obtained FDA approval on February 27, 2026, for Sogroya's expanded indications for various growth disorders, offering a once-weekly growth hormone alternative that is expected to improve treatment adherence and alleviate the burden of daily injections for families.
See More
Ascendis Pharma Plans 2026 U.S. Launch of YUVIWEL Following FDA Approval
- FDA Approval Milestone: Ascendis Pharma's YUVIWEL has received FDA approval as the first once-weekly treatment for children with achondroplasia, marking the company's third FDA-approved drug and significantly enhancing its competitive position in the rare disease market.
- Clinical Data Highlights: In the pivotal ApproaCH trial, children treated with navepegritide achieved an annualized growth velocity (AGV) of 5.9 cm/year compared to 4.4 cm/year for placebo, demonstrating a significant treatment difference of 1.5 cm/year, indicating the drug's clinical efficacy.
- Commercialization Strategy: Ascendis plans to support the commercial availability of YUVIWEL in early Q2 2026, expecting a premium pricing strategy, and aims to maximize market penetration through the Ascendis Signature Access Program, which includes reimbursement support and patient assistance.
- Market Opportunity and Future Milestones: Ascendis estimates approximately 2,600 pediatric patients with achondroplasia in the U.S., with plans to complete enrollment in a study for children aged 0-2 by 2026 and aims for European approval by the end of the year, further expanding market potential.
See More
